Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

SciTech Development Announces the Launch of Equity Crowdfunding Campaign

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

SciTech Development LLC, a specialty pharmaceutical company, has announced the launch of its equity crowdfunding campaign on StartEngine.

SciTech Development plans to grow the company, scale-up clinical drug manufacturing, and to commence the company’s first clinical trial of ST-001 nanoFenretinide for the treatment of non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphomas are cancers that begin in the lymphatic system, which is part of the body’s germ-fighting immune system.

SciTech Development notes their patented lead drug candidate ST-001 nanoFenretinide is a combination of the company’s proprietary drug delivery platform known as SDP, and fenretinide, a drug with a well-documented safety profile. We are also pleased to announce that ST-001 has an FDA approved Investigational New Drug Application (IND) and Orphan Drug Designation (ODD) for two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). ST-001 is ready to enter the clinic at Rush University Medical Center (RUMC) in Chicago, IL where it has IRB approval (Institutional Review Board).

Earle Holsapple, President of SciTech Development relays that FDA approval of ST-001 would be a significant step towards revenue generation, but more importantly, believes that SciTech’s scientific breakthroughs will have a profound impact on patients who are battling cancer.

Visit https://www.startengine.com/scitechdevelopment to invest in SciTech’s crowdfunding campaign, early investors qualify for time-based bonuses. For company, product, and investor information visit www.SciTechSDP.com. Detailed information regarding SciTech’s science and the company can be found at www.SciTechDevelopment.com.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine